Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders
Jonathan Gilley(University of Cambridge), Michael P. Coleman(Babraham Institute)
Cited by 82
Related Papers
Targeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective Potency<i>In Vivo</i>
|Journal of Neuroscience|2010|123
Alzheimer’s Disease: Etiology, Neuropathology and Pathogenesis
|Exon Publications eBooks|2020|93
NMNAT2 is a druggable target to drive neuronal NAD production
|Nature Communications|2024|36
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration
|bioRxiv (Cold Spring Harbor Laboratory)|2019|10